Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial.

Breast Cancer Res · 2025 · PMC12570423 · PMID 41152909

Europe PMC DOI

hedged sentence

0.5034

closest p · 10.1× alpha

0.5034

boldest claim

The sentences

did not reach statistical significanceP = 0.5034not close (p > 0.1)

47.1%), but the difference did not reach statistical significance ( P = 0.5034).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.